Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research

Gymnema and Reduced Low-Density Lipoprotein Level

Research synthesisLow evidenceSmall effect3 studies · 3 beneficial · 0 neutral · 0 harmful

Across 3 studies, all reported beneficial effects of Gymnema sylvestre on reducing low-density lipoprotein (LDL) cholesterol, with effect sizes ranging from small to moderate. The most-studied dose was 300 mg twice daily (600 mg/day), and effects were typically observed at 12 weeks. Evidence is derived from clinical populations, including patients with metabolic syndrome and impaired glucose tolerance.

  • Effective dose range: 300 mg twice daily (600 mg/day)
  • Studied populations: patients with metabolic syndrome, patients with impaired glucose tolerance

Caveats: Evidence base is small (only 3 studies) — conclusions should be considered preliminary. Available evidence is overwhelmingly positive — clinical literature in this area is subject to publication bias (null-result studies are less likely to be published or indexed). Two of the three studies had small sample sizes (24 and 30 participants), and one study reported only a borderline significant effect for VLDL rather than LDL directly.

Generated Jul 13, 2026
Doses used in studies
  • mg/day: 600 (median 600, IQR 600600) 2 studies
Time to effect
Median: 2.8 months · IQR 2.8 months2.8 months · Range 2.8 months2.8 months — Reported in 1 of 3 studies
3 of 3 papers
Back to top